On the HCPLive news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.
Xenofon Baraliakos, MD, PhD: Efficacy of Upadacitinib for Treating Active Ankylosing SpondylitisJune 3rd 2023
Results of the SELECT-AXIS 2 study supported the efficacy and safety profile of upadacitinib in patients with active ankylosing spondylitis who had an inadequate response to biologic DMARD therapy.
Iain McInnes, CBE, PhD: Long-Term Efficacy, Safety of Upadacitinib in Patients With Psoriatic ArthritisJune 3rd 2023
Over a 3-year period, patients treated with upadacitinib reported greater disease improvements and a greater mean change from baseline when compared with those receiving adalimumab.
Genetic Variants in STAT4 Linked to Disabling Pansclerotic Morphea: JAK Inhibition Shows Promising ResultsJune 2nd 2023
Gain-of-function STAT4 variants in patients with disabling pansclerotic morphea suggest a potential therapeutic role for JAK inhibition, resulting in improved clinical symptoms and inflammatory markers.
Pegloticase Use Could Contribute to Bone Remodeling in Gout PatientsJune 2nd 2023
An analysis of DECT imaging from the MIRROR trial is providing clinicians with insight into the potential for urate crystal resolution and bone remodeling with pegloticase plus methotrexate in patients with uncontrolled gout.
For People with Diabetes, Starting an SGLT2 Inhibitor Could Lower Gout RiskJune 2nd 2023
An analysis of more than 20,000 people with type 2 diabetes suggests initiating therapy with an SGLT2 inhibitor, as a second-line treatment to metformin, was associated with a lower risk of developing gout relative to other second-line therapies.
Ophthalmology Month in Review: May 2023June 1st 2023
Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our May 2023 month-in-review features new FDA approvals, the future of artificial intelligence in eye care, and interesting crossover coverage.
Pegloticase Use and Quality of Life in Uncontrolled Gout, with Brian LaMoreaux, MDJune 1st 2023
Brian LaMoreaux, MD, discusses data from an analysis of the MIRROR trial examining the impact of pegloticase plus methotrexate on patient-reported outcomes and quality of life measures among patients with uncontrolled gout.
Increased Risk of Venous Thromboembolism Identified in Individuals with Atopic DermatitisJune 1st 2023
New data indicating this connection suggests a need for clinicians to take into account cardiovascular examination for patients with both the skin disorder and symptoms suggestive of incident venous thromboembolism.